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Summary Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to
receive four course of mitozantrone, 14 mg m2 (n = 30) intravenously every 3 weeks (9 weeks total) or
megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease
control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective
response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in
all sites, including visceral metastases and receptor negative patients. There were no significant differences
between treatment groups in the median time (5 months each) to disease progression/response duration or
survival (13 months megesterol, II months mitozantrone) from commencing second-line therapy. Toxicity was
considerably higher in the mitozantrone group.
Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short
course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive.
Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth
consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy.
With current therapies available no patients is cured of
advanced breast cancer; treatment is palliative being directed
towards the relief of symptoms without compromise to the
quality of life that remains. Palliation depends upon a
balance between objective regression of symptomatic tumour
burden and toxicity of treatment. Within most centres of the
UK, endocrine manipulation remains the preferred initial
treatment provided death is not imminent. Tamoxifen is the
most popular initial treatment choice in postmenopausal
patients. Those patients that fail to respond to tamoxifen
have a very poor prognosis (Williams et al., 1986).
We have compared the synthetic progestogen, megesterol
acetate (Megace®, Bristol Myers, UK) against a 'soft option'
single-agent cytotoxic, mitozantrone (Novantrone®, Lederle,
UK) in terms of 1 year progression free rates and survival in
a group of patients who had shown no therapeutic response
to tamoxifen. It was not our intention to compare response
rates.
Patients and methods
Sixty postmenopausal advanced breast cancer patients who
had relapsed within 6 months of commencing tamoxifen were
entered into this prospective study. None had received
previous adjuvant therapies. Each was randomised to receive
either megesterol acetate, 160 mg bd. or mitozantrone 14 mg
m-2 every 3 weeks for four courses (i.e., for 9 weeks from
day 1). Thirty patients were randomised into each treatment
arm. Patients with brain metastases or jaundice were exclu-
ded. Pre-treatment performance status had to be two or less
on the World Health Organisation scale (World Health
Organisation, 1979). Patients failing to respond to either
second-line therapy then went on to receive combination
CMF if appropriate; patients with non-progressive disease
after four cycles of mitozantrone were randomised to stop
cytotoxic therapy or change to CMF. Ethical committee
approval and informed consent from all patients was
obtained.
The median age was 64 years (43-78) for those patients
receiving megesterol acetate and 61 years (42-75) for
mitozantrone. Major sites of disease are shown in Table I.
Chemotherapy continued unless the while cell count was
<2.5 x 109 1, platelets <100 x 109 1 ' or haemoglobin <10
g dl-1. Response and toxicity were determined using standard
UICC (Hayward et al., 1979) and WHO criteria (World
Health Organisation, 1979). The British Breast Group's
recommendation (British Breast Group, 1974) that the mini-
mum duration of remission be 6 months was also adhered.
The patients ECOG/WHO performance status was recorded
prior to treatment and at each assessment thereafter.
Primary tumour steroid receptor status was known in 51
patients; the oestrogen receptor assays having been perform-
ed at the Tenovus Institute, Cardiff using the commercial
ER-enzyme immunoassay (Abbot ER-Eia monoclonal). Oes-
trogen receptor was considered positive when a value > 15
fmol mg/cytosol protein was obtained (Walker et al., 1989).
The histological grade of the primary tumour (Elston, 1987)
was known in 54 patients.
Actuarial survival analysis was performed using the statis-
tical package SPSSX-21 life table analysis (SPSS, 1986) which
calculates Gehan's generalised Wilcoxon rank test for cen-
sored data (Lee & Desu, 1972). During the course of the
study it became evident that there was no early advantage for
the group randomised to single agent chemotherapy. Having
sought statistical advice (JH) the trial was abandoned once
sufficient events had occurred to allow for sufficient statistical
power in its analysis. With an expected response rate of
15-17% to megesterol in this treatment setting (Blackledge
et al., 1986; Robertson et al., 1989b) and 30-35% to mito-
zantrone (Morridsen et al., 1985; Harris et al., 1990) we
calculated that to have a 90% (9 in 10) chance (power) of
detecting an improvement from 15% to 35% in progression-
free rates at 1 year we would need 49 events in total (Freed-
man, 1982), the number of events observed, assuming
logrank comparison between time to progression curves.
Results
The overall objective response rate (18%) was poor; four
partial responses followed treatment with megesterol and
seven to mitozantrone. There were no complete responders in
either treatment arm. Stable disease of a minimum duration
of 6 months was recorded in seven patients (23%) treated by
megesterol acetate and four (13%) treated by mitozantrone;
38 patients (63%) had progressive disease. Thus, one in three
patients in each group had substantial disease control i.e.,
lack of progression for >6 months. Responses (partial and
static) were observed in all disease sites with the response
rate in liver secondaries, 3/8 (37%) to megesterol similar to
that seen with mitozantrone, 4/9 (44%). The response rates
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observed in other sites included: bone 5/12 (41%) for mege-
sterol and 5/14 (36%) for mitozantrone; lung 2/5 (40%) for
megesterol and 2/7 (28%) for mitozantrone; and 1/3 stage
IIIs treated by megesterol. Responsive disease and disease
stabilisations were seen in both receptor positive (10) and
negative (7) tumours (Table I).
Pretreatment characteristics (site of metastases, tumour
grade and oestrogen receptor status) known to effect prog-
nosis once metastases appear were evenly distributed
amongst the two treatment groups (Table II). There were no
differences in the median survival from starting second-line
treatments or time to disease progression as measured by
log-rank analysis (Figures 1 and 2). Confidence limits on the
difference in I year progression-free rates (diff = 0.2315-
0.1164 i.e., 0.1151) were: 95% confidence limits -0.095 to
0.325; 90% confidence limits -0.061 to 0.291. The negative
lower limits are in favour of megesterol acetate i.e., there is
only a 1 in 20 chance of the difference being more than 29%
in favour of mitozantrone.
Although quality of life was not formally measured, an
improvement in performance status was reported in eight
patients receiving chemotherapy and 11 megesterol. Fourteen
patients (46%) experienced nausea and vomiting (grade II in
seven, grade III in four) to the chemotherapy and three
developed stomatitis (grade I). All were prescribed prophy-
lactic metaclopramide (20 mg 8 hourly) as required. Alopecia
was reported by 12 (40%) patients, four of whom required a
wig. Ten patients (33%) reported no side effects of mitozan-
trone. Myelosuppression sufficient to cause a delay in the
3-weekly regimen and dose reduction occurred in four
patients, three of whom required a blood transfusion. One
patient developed an acute anaphylaxis requiring adrenaline,
hydrocortisone and 02, 2 h following her fourth dose of
mitozantrone. There were no cardiac toxic effects requiring
dose modification.
The toxicity and side effects of megesterol acetate were
minimal. The most commonly reported side-effects were
sweating/hot flushes (four patients), increased appetite and
weight gain. Four patients experienced a < 10% weight gain
and one a > 10% gain, the latter requiring a dose reduction
to 80 mg bd. The increased appetite was particularly welcom-
ed by three patients. There were no cases of hypercalcaemia,
venous thrombosis or cardiac failure due to fluid retention.
Table I Receptor status and response
Response Megesterol acetate Mitozantrone
ER +ve PR 2 2
SD 4 2
Prog 2 2
ER -ve PR 1 3
SD 1 2
Prog 14 16
Unknown PR 1 2
SD 2 -
Prog 3 1
Table II Pretreatment characteristics
Megesterol acetate Mitozantrone
Site ofdisease
Stage III 3 4
Bone 13 10
Pulmonary 2 3
Bone & Pulmonary 3 4
Visceral 9 9
Tumour grade
Grade 1 2 3
Grade2 11 12
Grade 3 12 14
Oestrogen receptor status
ER +ve 8 6
ER -ve 16 21
> 0.8-
U 0.6-
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0.4
O 0.2-
0.0
0 6 12 18 24 30
Months
Number Meg 30 28 24 18 12 3 2 0
entering Mit 30 25 17 12 8 5 2 1
Figure 1 Probability of survival from commencing second-line
megesterol or mitozantrone. -0-, Megace; -U-, mitozantrone.
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Figure 2 Duration of response in patients receiving mitozant-
rone or megesterol. -0-, Megace; ---, mitozantrone.
Discussion
The conventional treatment of those patients failing to show
a response to first-line tamoxifen is cytotoxic chemotherapy,
particularly with visceral disease (Henderson, 1986). Before
dismissing the option of further hormonal therapies, con-
sideration has to be given to the fact that long-term remis-
sions and improved survival are rarely seen in advanced
breast cancer treated with cytotoxic chemotherapy (Powels et
al., 1980), treatment is aimed at achieving palliative remission
of symptoms. We have compared for the first time a second-
line hormonal therapy against a 'soft option' single agent
cytotoxic in apparent hormone resistant breast cancer, irre-
spective of disease site provided that the disease was not
fulminate. Comparison was made between megesterol acetate
and mitozantrone, a single agent with substantial activity and
low toxicity (Harris et al., 1990).
Phase II studies have reported on mitozantrone as a single
agent in advanced breast cancer with widely varying results;
a literature review (Leyden et al., 1984) reporting a mean
response rate of only 17% (range 4-44%). The larger pub-
lished series are consistent in reporting objective response
rates of approximately 30% (Morrisden et al., 1985; Harris et
al., 1990). The response rate in our own series (Robertson et
al., 1989) of heavily pretreated patients, measured at 3 and 6
month assessments (14% and 15% respectively) lies at the
lower end of the reported range; 22% of patients in our
series had static disease.
Megesterol acetate has been used within our unit (Robert-
son et al., 1989b) as a second-line therapy following tamox-
ifen failure. Of 93 patients that had shown an initial objective
response/static disease after 6 months treatment with tamox-
ifen, upon later relapse, 62% of these subsequently showed
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non-progression of their disease following 6 months of mege-
sterol. Similar response rates have been observed by other
workers (Ross et al., 1982; Blackledge et al., 1986). Only
17% of the 66 patients who had progressed within 6 months
of commencing tamoxifen had non-progressive disease when
subsequently treated with megesterol (Robertson et al.,
1989b). As this latter result was similar to our experience
with the more toxic mitozantrone, it seemed sensible to
compare the two contrasting second-line treatments on a
randomised basis.
Although the number of patients entering into this study is
small there is clearly no great advantage in terms of pro-
gression-free survival to the single-agent cytotoxic, indeed the
negative lower confidence limits favours megesterol, the
number of events being more important than the actual
number of recruited patients. Megesterol acetate appears to
be as effective in controlling disease progression as a short 9
week course of single-agent mitozantrone in patients without
immediate life threatening disease who had failed to respond
to tamoxifen; megesterol gave disease control of more than 6
months duration in one patient in three. Toxicity was sub-
stantially lower with megesterol, giving rise to a higher
quality of palliative response in those patients who achieved
objective regression/stabilisation of their symptomatic
disease. Within the setting of an advanced breast cancer
clinic the side effects of increased appetite and weight gain
associated with megesterol are frequently desirable.
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